Table 3.

Prognostic factors for survival.

Characteristics	N	Deaths	Univariate analysis		Multivariate analysis
		N (%)	HR (95%CI)	p	HR (95%CI)	p
All patients	302 (100%)	30 (10%)
Age>60	179	22 (12,2%)	2,01 (1,21–2,81)	0,083
Male gender	144	21 (14,5%)	2,66 (1,90–3,42)	0,01	2,75 (1,91–3,59)	0,019
KPS<60	114	20 (17,5%)	9,01 (8,07–9,95)	<0,001	4,87 (3,87–5,87)	0,002
Relapsing cancer	177	27 (15,2%)	6,81 (5,63–7,99)	<0,001	3,05 [1,83-4,27]	0,073
Fever & respiratory symptoms	130	25 (19,2%)	6,90 (5,94–7,86)	<0,001	5,09 (4,11–6,07)	0,001
Lung cancer	42	8 (19,0%)	2,38 [1,58-3,18]	0,03
Covid-19 suspect CT Scan	59	9 (15,2%)	2,55 (1,63–3,47)	0,051
SARS-COV2 RT-PCR+	55	8 (14,5%)	1,92 (1,12–2,72)	0,1
CRP>50	133	22 (16,5%)	3,13 (2,23–4,03)	0,009
Ly < 700/μL	91	18 (19,7%)	4,84 (4,02–5,66)	<0,001	3,05 (2,19–3,91)	0,05
SARS-COV2 RT-PCR+ pts	55 (100%)	8 (14%)
Age>60	40	8 (20%)	33,9(27,4–40,5)	0,026
Male gender	26	7 (26,9%)	8,19 (6,09–10,3)	0,014
KPS<60	17	6 (35,2%)	7,7 (6,09–9,31)	0,005
Fever & respiratory symptoms	36	8 (22,2%)	36,9 (30,5–43,3)	0,017
Lung cancer	7	3 (42,9%)	4,69 [3,24-6,14]	0,16	ND
Covid-19 suspect CT scan	27	7 (25,9%)	0,89 (−0,64–2,42)	0,072
Relapsing cancer	31	7 (22,5%)	5,29 (3,19–7,39)	0,061
CRP >50	18	6 (66,6%)	6,87 (4,75–8,99)	0,039
Ly < 700/μL	13	3 (23,1%)	8,98 [6,71-11,3]	0,037
SARS-COV2 RT-PCR neg. pts	247	22 (8%)
Age>60	139	14 (10.1%)	1,4 (0,54–2,26)	0,43
Male gender	118	14 (11.9%)	1,97 (1,11–2,83)	0,11
KPS<60	97	19 (19.6%)	10,6 (9,38–11,82)	<0,001	6,64 (5,41–7,87)	0,003
Relapsing cancer	146	20 (13.7%)	7,5 (6,05–8,95)	<0,001	4,26 (2,79–5,73)	0,053
Fever & respiratory symptoms	94	17 (18.1%)	5,78 (4,78–6,78)	<0,001	4,9 (3,90–5,90)	0,002
Covid-19 suspect CT scan	32	2 (6.2%)	0,89 (−0,64–2,42)	0,87
CRP>50	115	16 (13.9%)	2,67 (1,67–3,67)	0,05
Ly < 700/μL	78	15 (19.2%)	4,39 [3,49-5,29]	0,001	2,16 (1,24–3,08)	0,09

HR, hazards ratio; CI, confidence interval; CT, computed tomography; KPS, Karnofsky performance status.